Fulgent Genetics FLGT Estimates

NASDAQ FLGT
$21.69 -0.16 (-0.73%)
At close: Sep 18, 2026 · 4:00 PM EDT
Analyst Estimates

Fulgent Genetics, Inc. Revenue Estimates

Periods 22
Next Period Q3 26
Consensus 82.52 M

Analysts expect Fulgent Genetics, Inc. to report revenue of 82.52 M for Q3 26, against a range of 74.37 M to 90.66 M. The most recent reported quarter, Q2 26, came in at 85.39 M, a 7.0% miss against the 91.82 M consensus.

Metric Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28Q1 29Q2 29Q3 29Q4 29
Reported (Actual) 71.74 M76.21 M73.46 M81.80 M84.07 M83.34 M71.14 M85.39 M--------
High Estimate 73.14 M73.82 M71.64 M76.59 M89.28 M87.22 M74.97 M95.18 M90.66 M101.33 M99.60 M95.58 M109.91 M112.66 M97.99 M120.39 M
Low Estimate 65.48 M68.49 M62.21 M71.36 M80.69 M76.91 M68.66 M88.45 M74.37 M83.78 M87.24 M80.70 M91.51 M97.51 M91.15 M102.74 M
Consensus Estimate 69.31 M71.15 M66.92 M73.98 M84.98 M82.07 M71.82 M91.82 M82.52 M92.55 M93.42 M88.14 M100.71 M105.08 M94.57 M111.56 M
Analyst Estimates

Fulgent Genetics, Inc. Earnings Per Share (EPS) Estimates

Periods 22
Next Period Q3 26
Consensus -0.69

Analysts expect Fulgent Genetics, Inc. to report earnings per share of -0.69 for Q3 26, against a range of -0.72 to -0.66. The most recent reported quarter, Q2 26, came in at -0.58, a 23.4% miss against the -0.47 consensus.

Metric Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28Q1 29Q2 29Q3 29Q4 29
Reported (Actual) 0.310.040.040.070.140.16-0.36-0.58--------
High Estimate -0.13-0.12-0.16-0.16-0.200.03-0.33-0.45-0.66-0.68-0.48-0.24-0.45-0.56-0.31-0.13
Low Estimate -0.15-0.14-0.18-0.20-0.220.03-0.39-0.49-0.72-0.78-0.58-0.26-0.51-0.66-0.37-0.15
Consensus Estimate -0.14-0.13-0.17-0.18-0.210.03-0.36-0.47-0.69-0.73-0.53-0.25-0.48-0.61-0.34-0.14